Sign inCreate account

Report workspace

Add to folder
NCT02470091COMPLETEDanonymous

Phase 2 Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma

Sponsor

Source record

Children's Oncology Group

Phase

Source record

PHASE2

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Denosumab, Laboratory Biomarker Analysis, Pharmacological Study

Indication / condition

AI-normalized

Metastatic Osteosarcoma

Intervention

Source record

Denosumab, Laboratory Biomarker Analysis, Pharmacological Study

Related intelligence directories

Indication directory: Metastatic OsteosarcomaModality directory: monoclonal antibodyTarget directory: Denosumab

Source & freshness

Source record

NCT ID

NCT02470091

Original source

ClinicalTrials.gov

Source last updated

Jan 22, 2024

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02470091

Title

Phase 2 Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma

Sponsor

Children's Oncology Group

Status

COMPLETED

Phase

PHASE2

Condition raw

Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Stage IV Osteosarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7

Condition normalized

Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Stage IV Osteosarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Denosumab, Laboratory Biomarker Analysis, Pharmacological Study

Target normalized

Denosumab, Laboratory Biomarker Analysis, Pharmacological Study

Interventions

Denosumab, Laboratory Biomarker Analysis, Pharmacological Study

Public preview

Source record

This phase II trial studies how well denosumab works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as denosumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase 2 Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT02470091

Status

COMPLETED

Phase

PHASE2

Sponsor

Children's Oncology Group

Executive brief

Investment-Ready Snapshot

This phase II trial studies how well denosumab works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as denosumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 22, 2024
Internal syncJun 18, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02470091

Indication

Metastatic Osteosarcoma

Modality

monoclonal antibody

Target

Denosumab, Laboratory Biomarker Analysis, Pharmacological Study

Intervention

Denosumab, Laboratory Biomarker Analysis, Pharmacological Study

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.